Advice
Following a full submission.
Fulvestrant is not recommended for use within NHS Scotland for the treatment of postmenopausal women with advanced breast cancer who relapse or progress following prior anti-oestrogen therapy. Fulvestrant is no more effective than aromatase inhibitors when used following the failure of tamoxifen, and it is approximately four times more expensive. There are no randomised clinical data on the use of fulvestrant following failure of aromatase inhibitors.
The licence holder has indicated their decision to resubmit.
Download detailed advice27KB (PDF)
Medicine details
- Medicine name:
- Fulvestrant (Faslodex®)
- SMC ID:
- 114/04
- Indication:
- Metastatic breast cancer
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 08 August 2004